ALDEYRA THE
NASDAQ: ALDX (Aldeyra Therapeutics, Inc.)
Kemas kini terakhir: 19 jam lalu1.34
-0.12 (-8.22%)
| Penutupan Terdahulu | 1.46 |
| Jumlah Dagangan | 1,564,610 |
| Harga / Buku (P/B) | 2.13 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.970 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.48% |
| Nisbah Semasa (MRQ) | 6.49 |
| Aliran Tunai Operasi (OCF TTM) | -45.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 32.70 M |
| Pulangan Atas Aset (ROA TTM) | -32.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Aldeyra Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.33 |
|
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.13% |
| % Dimiliki oleh Institusi | 56.79% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 5,475,516 |
| Kingdon Capital Management, L.L.C. | 30 Jun 2026 | 2,652,315 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |